



Fluidigm Announces Co-Marketing Agreement with Indica Labs to Offer Platform for Imaging Mass Cytometry Data Analysis to Aid Novel Digital Pathology Investigations

February 7, 2019

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM) and Indica Labs, Inc., today announced a co-marketing relationship for scalable and simple-to-use tissue image analysis for Imaging Mass Cytometry™ (IMC™). Under the terms of the agreement, Fluidigm and Indica Labs will cooperatively promote the next-generation digital pathology image analysis and image management platforms HALO®, HALO AI™ and HALO Link™ in conjunction with the Fluidigm® Hyperion™ Imaging System, MCD™ Viewer software and related Maxpar® antibodies and kits.

"We are excited to announce this important relationship with Fluidigm," said Indica Labs CEO Steven Hashagen. "The Hyperion Imaging System combined with our HALO image analysis capabilities represents a complete solution for multiplexing, especially in immuno-oncology, where the requirement for higher-multiplexed imaging data is on the rise."

Mass cytometry deeply profiles immune cell phenotypes and functions and is the basis of hundreds of peer-reviewed publications documenting research on the frontiers of immunology, immuno-oncology and other realms of health and disease. The Hyperion™ Imaging System extends the use of mass cytometry technology to imaging applications, revolutionizing high-plex tissue analysis by surpassing the inherent limitations of fluorescence detection. There are currently more than 50 commercially enabled IMC systems globally.

The potential of the Hyperion Imaging System in advancing immunology and immuno-oncology research was recently cited by the Life Science Industry Awards® as the basis for Fluidigm being named Company to Watch in 2019.

"Delivery of a new, highly accessible and scalable platform for data analysis is further evidence of a dynamic and growing ecosystem as developers of innovative analytical resources integrate their tools with our transformative technology," said Chris Linthwaite, President and CEO of Fluidigm. "Our agreement with Indica to offer HALO provides our customers in oncology, immuno-oncology and other critical research areas another tool to drive meaningful insights in health and disease."

HALO is an easy-to-use yet powerful platform for analysis of tissue biomarkers. The recent HALO 2.3 release and dynamic Highplex FL module add support for an unlimited number of biomarkers and cellular phenotypes, including the highly multiplexed IMC data generated from the Hyperion Imaging System. Combined with spatial analysis and tissue classification capabilities in HALO and HALO AI, the platforms provide a comprehensive solution for multiplexed data analysis in immuno-oncology and beyond. Support for IMC data in HALO Link allows users to share, manage, mine and view images and image analysis, facilitating collaboration with other researchers.

About Indica Labs

Indica Labs software solutions provide fast, quantitative evaluation of whole slide tissues using HALO and HALO AI for image analysis and HALO Link for image and data management and sharing. With unmatched ease-of-use and scalability, pharmaceutical, healthcare, and research organizations worldwide are using HALO for high-throughput, whole-slide image quantification in areas such as oncology, immuno-oncology, neuroscience, ophthalmology, metabolism, respiratory, and toxicological pathology.

About Fluidigm

Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.

Fluidigm, the Fluidigm logo, CyTOF, Hyperion, Imaging Mass Cytometry, IMC, Maxpar, and MCD are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Indica:

Kate Lillard Tunstall, PhD
Chief Scientific Officer
+44 (0)1789 765 721
kate@indicalab.com

Fluidigm Media:

Michaeline Bunting
Senior Director, Marketing

650 737 4190

michaeline.bunting@fluidigm.com

Fluidigm Investors:

Agnes Lee

Vice President, Investor Relations

650 416 7423

agnes.lee@fluidigm.com



Source: Fluidigm Corporation